BIT

6.67%

3.2¢ biotron limited

Ann: POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV, page-216

First 216 Last

Share
Profile

Follow
CatmanRules

2,037 Posts.

587

07/04/24

13:21

Post #: 73226458
Share

Originally posted by Batmansdaughter: ↑

Just a quicky after reading some above, particularly Nails&glue's analysis

without seeing the full data set, I'm confident by these headline results shown thus far because there easiest interpretation state that the trial has achieved its purpose. They can't say that and later release data that does not support it, and unfortunately I don't have a conspiratorial bone in my body, and if I did, I'd rip it out!

It is not possible to provide detailed analysis without the full data set. Comments above stating that the results seem to be no different from previous trial are premature. Most importantly though, it is the analysis of the full results in light of 6 more years of learning that has to be considered. HIV is a ocmplex disease and many unknowns still remain, and even though the latest ART has improved, any new progress will be well recieved.

The importance of rapid reduction in plasma viral load is critical because it enables higher levels of CD4 T cells to maintained. These cells are the primary immunity response cells, but many other cells involed in the equation and are too numerous to mention now. Keep in mind though that CD4 cell counts are a principle measure of disease progression.

They are actually prone to be latched upon by HIV cells prior to penetration and replication, utilizing its Vpu viroporin, just as SARS2 uses its own E viroporin to penetrate. Then viral assemby rapidly occurs leaving to CD4 cell death rapid generation of new virus, resulting in a weakened immunity from the twofold effect of having less CD4 cells and more virus that goes on to further replicate. Hence the need for rapid intervention.

The cytokine storm that we became familiar with C19 also plays a part here.

Any drug that reduces viral load quicker will most likely be well received, especially if it has a new mode of action and with immuntherapy benefits. The oustanding data analysis will shed light on how the immune system benefits, which was lacking in the previous trial.

Nothing wrong now.

Expand

sorry if already posted !

personally believe we are major DERISKED now ---

Bring on next news - EXCITING TIMES

BIT Price at posting: 8.2¢ Sentiment: Buy Disclosure: Held
22 Upvote

3 Great analysis

Reply

Top Stories

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

IGO

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

ASX Market Open: ASX200 to rise for Friday session | July 26

MIN

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

HRZ

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Nine's staff strike as Paris Olympic coverage begins

RHK

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

MND

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

There are more pages in this discussion • 82 more messages in this thread...

First 216 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 3.2¢		Change 0.002(6.67%)		Mkt cap ! $28.87M

Open	High	Low	Value	Volume
3.1¢	3.3¢	3.1¢	$13.79K	424.2K

Buyers (Bids)

No.	Vol.	Price($)
1	329429	3.2¢

Sellers (Offers)

Price($)	Vol.	No.
3.4¢	100000	1

View Market Depth

No.	Vol.	Price($)
1	329429	0.032
3	81516	0.031
9	375471	0.030
3	1008888	0.029
4	468000	0.028

Price($)	Vol.	No.
0.034	100000	1
0.035	436199	5
0.037	537816	2
0.038	162500	1
0.039	317353	2

Last trade - 15.51pm 26/07/2024 (20 minute delay)

BIT (ASX) Chart

Ann: POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV, page-216

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

ASX Market Open: ASX200 to rise for Friday session | July 26

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Nine's staff strike as Paris Olympic coverage begins

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV, page-216

Top Stories

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

ASX Market Open: ASX200 to rise for Friday session | July 26

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Nine's staff strike as Paris Olympic coverage begins

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News